[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354200-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354200-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ube2c-promotes-pancreatic-cancer-progression-through-pi3kaktmtor-signaling-pathway","UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway","","UBE2C, a key member of the ubiquitin-proteasome system, is overexpressed in various malignant tumors and correlates with poor prognosis. Findings show UBE2C is elevated in pancreatic cancer cell lines and tissues versus normal counterparts, and the aberrant expression links to poor outcomes. UBE2C knockdown reduces proliferation, migration, and invasion and lowers PI3K/AKT/mTOR pathway phosphorylation. SC79, a pathway activator, reverses these effects. Results indicate UBE2C promotes pancreatic cancer via PI3K/AKT/mTOR signaling and may serve as a biomarker and therapeutic target.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ube2c-promotes-pancreatic-cancer-progression-through-pi3kaktmtor-signaling-pathway/354200/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ube2c-promotes-pancreatic-cancer-progression-through-pi3kaktmtor-signaling-pathway/354200.png","ImageObject",300,407,{"name":42,"@type":43},"Cart","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does UBE2C play in pancreatic cancer progression?","Question",{"text":63,"@type":64},"UBE2C is overexpressed in pancreatic cancer cells and tissues and is associated with poor prognosis. Its knockdown reduces key malignant behaviors including proliferation, migration, and invasion.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does UBE2C affect the PI3K/AKT/mTOR signaling pathway?",{"text":68,"@type":64},"UBE2C knockdown significantly decreases phosphorylation within the PI3K/AKT/mTOR pathway, indicating reduced pathway activation.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the effect of activating the pathway with SC79?",{"text":72,"@type":64},"SC79 reverses the inhibitory effects of UBE2C knockdown on PI3K/AKT/mTOR phosphorylation and restores proliferation, migration, and invasion of pancreatic cancer cells.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354200,1790870228,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","CELL CYCLE  \n2026, VOL. 25, NO. 1, 1–12  \n[https://doi.org/10.1080/15384101.2026.2668450](https://doi.org/10.1080/15384101.2026.2668450)  \nRESEARCH ARTICLE     \nUBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway  \nZhou Zhou a*, Yuhang Chenb,c* and Ping Lia  \naOncology Department of Integrated Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, He Fei, Anhui, China; bDepartment of Integrative Oncology, Fudan University, Shanghai, China; cDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China  \nABSTRACT  \nUBE2C, a key member of the ubiquitin-proteasome system, is overexpressed in various malignant tumors and correlates with poor prognosis. Our findings reveal that UBE2C expression is elevated in both pancreatic cancer cell lines and tissues compared to normal pancreatic cells and tissues, with this aberrant expression linked to a poor prognosis. Knockdown of UBE2C expression reduces pancreatic cancer cell proliferation, migration, and invasion, while significantly decreasing the phosphorylation of the PI3K/ AKT/mTOR signaling pathway. Administration of the pathway activator SC79 reverses the inhibitory effects of UBE2C knockdown on the PI3K/AKT/mTOR pathway, restoring the proliferation, migration, and invasion of pancreatic cancer cells. These results suggest that UBE2C promotes pancreatic cancer progression via the PI3K/AKT/mTOR signaling pathway. Thus, UBE2C serves as a potential biomarker for the early detection and diagnosis of pancreatic cancer and may represent a promising therapeutic target.  \nARTICLE HISTORY  \nReceived 11 July 2025 Revised 24 February 2026 Accepted 28 April 2026  \nKEYWORDS  \nUBE2C; pancreatic cancer; PI3K; AKT; mTOR  \nIntroduction  \nThe incidence of pancreatic cancer has increased slightly in recent years, coinciding with rising rates of alcohol consumption, obesity, and diabetes. According to GLOBOCAN data, approximately 496,000 new cases of pancreatic cancer and 466,000 related deaths occurred globally in 2020. While pancreatic cancer ranks as the 14th most common cancer worldwide, it has a poor prognosis, being the seventh leading cause of cancer death in both men and women, with projections suggesting it will surpass breast cancer as the third leading cause of cancer death by 2025 [1] . The poor prognosis is primarily attributed to its insidious onset and late detection; by the time of diagnosis, 50%-60% of patients exhibit distant metastases, and 25% - 30% are diagnosed with locally advanced disease [2] . Despite advances in neoadjuvant therapy and surgical techniques, the 5-year survival rate for patients with resected pancreatic cancer has reached only 20%-30%[3,4], with a high recurrence rate of 70%-80%[5] . The development of chemotherapy has extended the median overall survival (mOS) of patients with unresectable locally advanced or metastatic pancreatic cancer to 8.5 months [6] to 11.1 months [7] . However, the overall prognosis for advanced pancreatic cancer remains poor, with incidence and mortality rates nearly identical. Thus, further exploration of biomarkers and potential therapeutic targets for the early diagnosis and treatment of pancreatic cancer is urgently needed. Recent research in cancer genomics has identified the PI3K/AKT/mTOR signaling pathway as one of the most frequently dysregulated pathways in patients with cancer [8] . PIK3CA mutations occur in 11%-14% of cases across various cancers, including lung [9], breast [10], stomach [11], and ovarian cancers [12] . Additionally, mutations in AKT and mTOR contribute to tumor cell proliferation, invasion, epithelialmesenchymal transition (EMT), and drug resistance [13] . Jia-Cheng Xu’s study demonstrated that NETO2 promotes the proliferation and metastasis of esophageal cancer cells via the PI3K/AKT and ERK pathways [14] . Wei-wei Liu’s research found that Circ-ZEB1 upregulates PIK3CA by silencing miR-199a-3p, thereby  \nCONTACT Ping L","cbCaiqyl76sOZRZa","https://ap.wps.com/l/cbCaiqyl76sOZRZa","pdf",3643164,12,"English","# Introduction","[{\"question\":\"What role does UBE2C play in pancreatic cancer progression?\",\"answer\":\"UBE2C is overexpressed in pancreatic cancer cells and tissues and is associated with poor prognosis. Its knockdown reduces key malignant behaviors including proliferation, migration, and invasion.\"},{\"question\":\"How does UBE2C affect the PI3K/AKT/mTOR signaling pathway?\",\"answer\":\"UBE2C knockdown significantly decreases phosphorylation within the PI3K/AKT/mTOR pathway, indicating reduced pathway activation.\"},{\"question\":\"What is the effect of activating the pathway with SC79?\",\"answer\":\"SC79 reverses the inhibitory effects of UBE2C knockdown on PI3K/AKT/mTOR phosphorylation and restores proliferation, migration, and invasion of pancreatic cancer cells.\"}]","UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway | PDF",1790109441,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/407b9b92c5743fb2ab1b67d0e3628824.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a18f9923f002a9ea03790f6b06378181.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0fc7d0b066171b1c65362a1f5e4e1bb7.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c317b69d0d708eef3f923b00f1beb720.webp",980,1306]